



Advances in Polycystic Ovary Syndrome Research: From Molecular Mechanisms to Therapeutic Strategies

Guest Editor:

Dr. Ebrahim Asadi

Department of Biology, University
of Saskatchewan, Saskatoon, SK
S7N 5E2, Canada

Deadline for manuscript
submissions:

31 May 2024

Message from the Guest Editor

Dear Colleagues,

Polycystic ovary syndrome (PCOS) is one of the most common endocrine and metabolic disorders of women of reproductive age, which negatively affects the reproductive and mental health of women. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary morphology are diagnostic criteria of PCOS. While obesity, increased cardiovascular risk factors, insulin resistance, hyperinsulinism, and type 2 diabetes mellitus are common symptoms among women with PCOS, they are not required criteria for diagnosis. Since PCOS leads to infertility, early diagnosis and treatments are critical, particularly at the extreme ends of the reproductive lifespan. Therefore, in recent years, understanding the underlying mechanisms, diagnosis, and clinical management of PCOS have become increasingly significant.

This Special Issue of “Advances in Polycystic Ovary Syndrome Research” will include original research articles and review articles addressing recent advances in our knowledge about etiology, pathophysiology and diagnosis of PCOS as well as advances in therapeutic options for managing PCOS.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access:— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[@Biomed_MDPI](https://twitter.com/Biomed_MDPI)